Inflammation and immune activation are associated with risk of Mycobacterium tuberculosis infection in BCG-vaccinated infants
Journal article
Satti I. et al, (2022), Nature Communications, 13
Metabolomics detects clinically silent neuroinflammatory lesions earlier than neurofilament-light chain in a focal multiple sclerosis animal model
Journal article
Yeo T. et al, (2022), Journal of Neuroinflammation, 19
Functional in-vitro evaluation of the non-specific effects of BCG vaccination in a randomised controlled clinical study.
Journal article
Wilkie M. et al, (2022), Scientific reports, 12
Chronovaccination: Harnessing circadian rhythms to optimize immunisation strategies.
Journal article
Otasowie CO. et al, (2022), Frontiers in immunology, 13
Distinct blood transcriptomic signature of treatment in latent tuberculosis infected individuals at risk of developing active disease.
Journal article
Burel JG. et al, (2021), Tuberculosis (Edinburgh, Scotland), 131
High-dose Mycobacterium tuberculosis aerosol challenge cannot overcome BCG-induced protection in Chinese origin cynomolgus macaques; implications of natural resistance for vaccine evaluation.
Journal article
Sibley L. et al, (2021), Scientific reports, 11
Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
Journal article
Barrett JR. et al, (2021), Nature Medicine, 27, 1113 - 1113
Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
Journal article
Ewer KJ. et al, (2021), Nature Medicine, 27, 1116 - 1116
MMR Vaccine Attitude and Uptake Research in the United Kingdom: A Critical Review
Journal article
Torracinta L. et al, (2021), Vaccines, 9, 402 - 402
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
Journal article
Voysey M. et al, (2021), The Lancet, 397, 881 - 891
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
Journal article
Barrett JR. et al, (2021), Nature Medicine, 27, 279 - 288
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
Journal article
Ewer KJ. et al, (2021), Nature Medicine, 27, 270 - 278
A non-human primate in vitro functional assay for the early evaluation of TB vaccine candidates.
Journal article
Tanner R. et al, (2021), NPJ vaccines, 6
Induction of Functional Specific Antibodies, IgG-Secreting Plasmablasts and Memory B Cells Following BCG Vaccination.
Journal article
Bitencourt J. et al, (2021), Frontiers in immunology, 12
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
Journal article
Voysey M. et al, (2021), The Lancet, 397, 99 - 111
The in vitro direct mycobacterial growth inhibition assay (MGIA) for the early evaluation of TB vaccine candidates and assessment of protective immunity: a protocol for non-human primate cells.
Journal article
Tanner R. et al, (2021), F1000Research, 10
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
Journal article
Ramasamy MN. et al, (2020), The Lancet, 396, 1979 - 1993
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
Journal article
Folegatti PM. et al, (2020), The Lancet, 396, 467 - 478
Adaption of the ex vivo mycobacterial growth inhibition assay for use with murine lung cells.
Journal article
Painter H. et al, (2020), Scientific reports, 10
Cytomegalovirus infection is a risk factor for tuberculosis disease in infants.
Journal article
Müller J. et al, (2019), JCI insight, 4